Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 369-378

  Saad, Fred ^a   Eastham, James A ^b   Smith, Matthew R ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bisphosphonate; Bone loss; Bone metastases; Bone mineral density; Bone turnover markers; Prostate cancer

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; HORMONE DERIVATIVE; ZOLEDRONIC ACID;

BONE METABOLISM; BONE METASTASIS; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CORRELATION ANALYSIS; DISEASE SEVERITY; HUMAN; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COLLAGEN TYPE I; DISEASE PROGRESSION; HUMANS; MALE; PEPTIDES; PROSTATIC NEOPLASMS;

EID: 84862986051     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.007     Document Type: Review

References (73)

1. Garcia M., Jemal A., Ward E.M. Global Cancer Facts and Figures, 2007 2007, American Cancer Society, Atlanta, GA.
2. Lipton A. Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J Support Oncol 2004, 2:205-213. Discussion 13-14, 16-17, 19-20.
3. Roato I., D'Amelio P., Gorassini E., et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008, 3:e3627.
4. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000, 88(12 Suppl):2919-2926.
5. Conde F.A., Sarna L., Oka R.K., et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 2004, 64:335-340.
6. Smith M.R., McGovern F.J., Fallon M.A., et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238-2245.
7. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361-2367. Discussion 7.
8. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
9. Oefelein M.G., Ricchiuti V., Conrad W., et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005-1007.
10. Saad F., Lipton A., Cook R., et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
11. Pavlakis N., Schmidt R., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005, (3). CD003474.
12. Coleman R.E. Bisphosphonates: Clinical experience. Oncologist 2004, 9(Suppl 4):14-27.
13. Saad F., Adachi J.D., Brown J.P., et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008, 26:5465-5476.
14. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
15. Ishizaka K., Machida T., Kobayashi S., et al. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007, 14:1071-1075.
16. Israeli R.S., Rosenberg S.J., Saltzstein D.R., et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007, 5:271-277.
17. Magno C., Anastasi G., Morabito N., et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate. Eur Urol 2005, 47:575-580. Discussion 80.
18. Planas J., Trilla E., Raventos C., et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009, 104:1637-1640.
19. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
20. Guadalupe-Grau A., Fuentes T., Guerra B., et al. Exercise and bone mass in adults. Sports Med 2009, 39:439-468.
21. Fohr B., Dunstan C.R., Seibel M.J. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003, 88:5059-5075.
22. Simmons M.N., Stephenson A.J., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007, 51:1175-1184.
23. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005, 23:2918-2925.
24. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
25. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
26. Cook R.J., Coleman R., Brown J., et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006, 12(11 Pt 1):3361-3367.
27. Smith M.R., Cook R.J., Coleman R., et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007, 70:315-319.
28. Lein M., Wirth M., Miller K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007, 52:1381-1387.
29. Lein M., Miller K., Wirth M., et al. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 2009, 69:624-632.
30. Noguchi M., Yahara J., Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003, 61:993-998.
31. Saad F. N-telopeptide of type I collagen (NTX) response to zoledronic acid in patients with bone metastases from prostate cancer. Proceedings of the Société Internationale d'Urologie (SIU) World Uro-Oncology Update Meeting; November, 2008; Santiago, Chile. [Abstract 411].
32. Jagdev S.P., Purohit P., Heatley S., et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001, 12:1433-1438.
33. Fizazi K., Lipton A., Mariette X., et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564-1571.
34. Fizazi K., Bosserman L., Gao G., et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial. J Urol 2009, 182:509-515. Discussion 15-6.
35. Zafeirakis A., Papatheodorou G., Arhontakis A., et al. Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases. Eur J Nucl Med Mol Imaging 2010, 37:103-113.
36. Leeming D.J., Koizumi M., Byrjalsen I., et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15:32-38.
37. Costa L., Demers L.M., Gouveia-Oliveira A., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002, 20:850-856.
38. Koizumi M., Yonese J., Fukui I., et al. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001, 87:348-351.
39. Zafeirakis A.G., Papatheodorou G.A., Limouris G.S. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases. Nucl Med Commun 2010, 31:249-253.
40. Kataoka A., Yuasa T., Kageyama S., et al. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol) 2006, 18:480-484.
41. Koopmans N., de Jong I.J., Breeuwsma A.J., et al. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: A longitudinal approach. J Urol 2007, 178(3 Pt 1):849-853. Discussion 53; quiz 1129.
42. Lyubimova N.V., Pashkov M.V., Tyulyandin S.A., et al. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 2004, 138:77-79.
43. Salminen E., Ala-Houhala M., Korpela J., et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 2005, 44:742-747.
44. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791.
45. Jung K., Lein M., von Hosslin K., et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 2001, 47:2061-2063.
46. Ramankulov A., Lein M., Kristiansen G., et al. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007, 67:330-340.
47. Ramankulov A., Lein M., Kristiansen G., et al. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 2007, 133:643-652.
48. Alibhai S.M., Gogov S., Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Crit Rev Oncol Hematol 2006, 60:201-215.
49. Chang S.S. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: Implications in the management of prostate cancer. Urology 2003, 62(6 Suppl 1):29-35.
50. Kastelan D., Giljevic Z., Kraljevic I., et al. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males. Med Hypotheses 2006, 67:1052-1053.
51. Araujo A.B., Travison T.G., Leder B.Z., et al. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 2008, 93:2135-2141.
52. Paller C.J., Shiels M.S., Rohrmann S., et al. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. Clin Endocrinol (Oxf) 2009, 70:26-34.
53. Basaria S., Lieb J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56:779-786.
54. Michaelson M.D., Marujo R.M., Smith M.R. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 2004, 10:2705-2708.
55. Brufsky A., Harker G., Beck T., et al. Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: A 5-year study (Z-FAST). Cancer Res 2009, 69(2 Suppl). [Abstract2067].
56. Taxel P., Dowsett R., Richter L., et al. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010, [Epub ahead of print].
57. Greenspan S.L., Nelson J.B., Trump D.L., et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008, 26:4426-4434.
58. Smith M.R., Saad F., Egerdie B., et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009, 182:2670-2675.
59. Ton F.N., Gunawardene S.C., Lee H., et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005, 20:464-470.
60. Ignatoski K.M., Friedman J., Escara-Wilke J., et al. Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: Interleukin-6 response is a potential early indicator of response to therapy. J Interferon Cytokine Res 2009, 29:105-112.
61. Lorente J.A., Valenzuela H., Morote J., et al. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999, 26:625-632.
62. Hegele A., Wahl H.G., Varga Z., et al. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 2007, 99:330-334.
63. Garnero P., Buchs N., Zekri J., et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000, 82:858-864.
64. Lipton A., Chapman J., Demers L., et al. Use of elevated bone turnover to predict bone metastasis. J Clin Oncol 2008, 26(Suppl):28s. Abstract 591.
65. Seibel M.J., Naganathan V., Barton I., et al. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004, 19:323-329.
66. Heller W., Harzmann R., Bichler K.H., et al. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases. Curr Probl Clin Biochem 1979, 9:249-256.
67. Berruti A., Dogliotti L., Gorzegno G., et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999, 45(8 Pt 1):1240-1247.
68. Koizumi M., Takahashi S., Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003, 23(5b):4095-4099.
69. Ali S.M., Demers L.M., Leitzel K., et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004, 15:455-459.
70. Coleman R.E., Cook R.J., Saad F., et al. Meta-analysis of effects of zoledronic acid on survival in patients with metastatic bone disease and high bone turnover. Cancer Treat Rev 2008, 34:S89. [Abstract P81].
71. Erem C., Tanakol R., Alagol F., et al. Relationship of bone turnover parameters, endogenous hormones and vitamin D deficiency to hip fracture in elderly postmenopausal women. Int J Clin Pract 2002, 56:333-337.
72. Slovik D.M., Gundberg C.M., Neer R.M., et al. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab 1984, 59:228-230.
73. Capeller B., Caffier H., Sutterlin M.W., et al. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 2003, 23(2A):1011-1015.